Vulcan Value Partners Highlights Elevance Health's Recovery Amid Post-Covid Adjustments
In its Q2 2026 investor letter, Vulcan Value Partners highlighted the strong performance of several investment strategies and identified Elevance Health (NYSE:ELV) as a notable contributor. The firm noted that while government-sponsored plans like Medicaid and Medicare Advantage have faced margin pressures due to post-Covid challenges, it expects earnings growth for Elevance to return next year. Elevance closed at $375.98 per share on July 29 with a market cap of $81.54 billion. Despite a one-month decline of -10.03%, the stock has gained 32.82% over the past 52 weeks, indicating investor confidence in its long-term potential. Vulcan Value Partners emphasized that Elevance's fundamentals remain strong and that discounted shares are beginning to recover as market recognition grows.
Topics: Elevance Health healthcare sector stock performance Vulcan Value Partners